Lexicon Pharmaceuticals, Inc.
NASDAQ:LXRX · NASDAQ Global Select
-$0.05 today
Vol 3.77M · Avg 2.48M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Stock Ticker Earnings Waterfall
NASDAQ:LXRX · Revenue to Net Income
Key Ratios
Analysis
$69.6M of revenue converted into -$26.1M of net income for the selected period. Gross margin is 98.2% and net margin is -91.6%, showing how much revenue survives after costs and taxes. EPS is $-0.07, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $49.8M +60.2% | $31.1M +2481.5% | $1.2M +766.2% | $139.0K -53.4% | $298.0K | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $274.0K -55.5% | $616.0K -99.0% | $59.0M +12.3% | $52.5M -4.6% | $55.0M | $725.6M | $804.0M | $882.4M |
| Gross Profit | $49.5M +62.6% | $30.5M +152.7% | -$57.8M -10.3% | -$52.4M +4.3% | -$54.7M | $8.9B | $7.6B | $6.2B |
| Gross Margin | 99.4% +1.4pp | 98.0% +4896.0pp | -4798.0% +32883.3pp | -37681.3% -19309.5pp | -18371.8% | 9.8% | 28.9% | 38.3% |
| Research & Development | $61.1M -27.7% | $84.5M +43.5% | $58.9M +11.5% | $52.8M -4.1% | $55.0M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $37.3M -71.7% | $131.9M | $0 | $0 | $0 | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $98.4M -56.7% | $227.6M +99.7% | $114.0M +135.6% | $48.4M +49.6% | $32.3M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $621.0K +16.3% | $534.0K -3.6% | $554.0K +29.7% | $427.0K +46.2% | $292.0K | $374.2M | $1.2B | $631.8M |
| EBITDA | -$41.4M +77.5% | -$184.3M -8.6% | -$169.8M -69.7% | -$100.0M -15.4% | -$86.7M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | -83.1% +509.8pp | -592.9% +13506.4pp | -14099.3% +57866.9pp | -71966.2% -42884.3pp | -29081.9% | 5.6% | 46.3% | 42.0% |
| Operating Income | -$48.9M +75.2% | -$197.1M -14.8% | -$171.8M -70.5% | -$100.8M -15.7% | -$87.1M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | -98.2% +536.0pp | -634.2% +13630.7pp | -14265.0% +58224.3pp | -72489.2% -43264.4pp | -29224.8% | 16.6% | 24.1% | 22.0% |
| Interest Income | $6.9M -43.8% | $12.3M +59.0% | $7.7M +384.5% | $1.6M +1091.0% | $134.0K | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $8.3M -46.5% | $15.6M +18.9% | $13.1M +371.3% | $2.8M +246.6% | $802.0K | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | -$1.4M +56.5% | -$3.3M +38.8% | -$5.4M -353.5% | -$1.2M -77.2% | -$668.0K | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | -$50.3M +74.9% | -$200.4M -13.1% | -$177.1M -73.7% | -$101.9M -16.2% | -$87.8M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | -101.1% +543.7pp | -644.8% +14066.1pp | -14710.9% +58630.1pp | -73341.0% -43892.0pp | -29449.0% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $1.3B | -$1.6B | $745.2M |
| Net Income | -$50.3M +74.9% | -$200.4M -13.1% | -$177.1M -73.7% | -$101.9M -16.2% | -$87.8M | $4.9B | $4.8B | $4.7B |
| Net Margin | -101.1% +543.7pp | -644.8% +14066.1pp | -14710.9% +58630.1pp | -73341.0% -43892.0pp | -29449.0% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | -$0 +77.8% | -$1 +21.3% | -$1 -29.0% | -$1 -1.6% | -$1 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | -$0 +77.8% | -$1 +21.3% | -$1 -29.0% | -$1 -1.6% | -$1 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $363.1M +13.4% | $320.0M +44.7% | $221.1M +33.4% | $165.7M +13.8% | $145.7M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $363.1M +13.4% | $320.0M +44.7% | $221.1M +33.4% | $165.7M +13.8% | $145.7M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
RAPT Therapeutics, Inc.
RAPT
$959.26M
Omeros Corporation
NASDAQ:OMER
$732.80M
4D Molecular Therapeutics, Inc.
NASDAQ:FDMT
$500.81M
Ocugen, Inc.
NASDAQ:OCGN
$428.23M
Compass Therapeutics, Inc.
NASDAQ:CMPX
$281.41M
Bicycle Therapeutics plc
NASDAQ:BCYC
$277.23M
Neumora Therapeutics, Inc. Common Stock
NASDAQ:NMRA
$268.92M
Fulcrum Therapeutics, Inc.
NASDAQ:FULC
$188.85M
ADC Therapeutics S.A.
NYSE:ADCT
$138.64M
Gossamer Bio, Inc.
GOSS
$39.29M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does LXRX generate?
Lexicon Pharmaceuticals, Inc. (LXRX) reported $49.80M of revenue in fiscal 2025.
Is LXRX profitable?
Lexicon Pharmaceuticals, Inc. (LXRX) reported -$50,341,000.00 of net income, with a net margin of -101.1%.
Explore More
Continue the stock analysis
Jump to another research area for this company.